

Barry L Shulkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9471990/publications.pdf>

Version: 2024-02-01

250
papers

8,630
citations

36203

51
h-index

58464

82
g-index

269
all docs

269
docs citations

269
times ranked

6754
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary hypothyroidism in childhood cancer survivors: Prevalence, risk factors, and long-term consequences. <i>Cancer</i> , 2022, 128, 606-614.	2.0	11
2	Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. <i>Journal of Clinical Oncology</i> , 2022, 40, 335-344.	0.8	46
3	Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29644.	0.8	18
4	Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma. <i>Clinical and Translational Radiation Oncology</i> , 2022, 34, 42-50.	0.9	2
5	Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3852-3869.	3.3	14
6	Impact of diagnostic and end-of-induction Curie scores in tandem autologous hematopoietic cell transplant for patients with high-risk neuroblastoma: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10027-10027.	0.8	0
7	A pilot induction regimen incorporating dinutuximab and sargramostim for the treatment of newly diagnosed high-risk neuroblastoma: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2022, 40, 10003-10003.	0.8	6
8	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 4107-4118.	0.8	11
9	Questions and comments about "Pediatric applications of Dotatate: early diagnostic and therapeutic experience". <i>Pediatric Radiology</i> , 2021, 51, 495-496.	1.1	1
10	Effect of Propranolol on 18F-Fluorodeoxyglucose Uptake in Brown Adipose Tissue in Children and Young Adults with Neoplastic Diseases. <i>Molecular Imaging and Biology</i> , 2021, 23, 260-269.	1.3	8
11	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. <i>Clinical Cancer Research</i> , 2021, 27, 2179-2189.	3.2	95
12	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 490.e1-490.e8.	0.6	14
13	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	3.2	42
14	Value of the Sentinel Node Procedure in Pediatric Extremity Rhabdomyosarcoma: A Systematic Review and Retrospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 9048-9059.	0.7	7
15	A safety and feasibility trial of ¹³¹ I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29117.	0.8	17
16	ASO Visual Abstract: The Value of the Sentinel Node Procedure in Pediatric Extremity Rhabdomyosarcoma: A Systematic Review and Retrospective Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 472-473.	0.7	0
17	Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. <i>Journal of Clinical Oncology</i> , 2021, 39, 2276-2283.	0.8	31
18	[11C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.120.261891.	2.8	4

#	ARTICLE	IF	CITATIONS
19	Metabolic response as assessed by ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or high-risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. <i>Cancer Medicine</i> , 2021, 10, 857-866.	1.3	18
20	Induction Chemotherapy With an Anti-GD2 Monoclonal Antibody (Dinutuximab) and Cytokines in Children With Newly Diagnosed High-risk Neuroblastoma: A Case Series. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e692-e696.	0.3	8
21	SNMMI Procedure Standard/EANM Practice Guideline on Pediatric ¹⁸ F-FDG PET/CT for Oncology 1.0. <i>Journal of Nuclear Medicine</i> , 2021, 62, 99-110.	2.8	53
22	Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3927-3937.	0.8	16
23	Pediatric Nuclear Medicine: Technical Aspects. , 2021, , .		0
24	Biochemical testing for neuroblastoma using plasma free 3-methyldopa, 3-methoxytyramine, and normetanephrine. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28081.	0.8	14
25	¹⁸ F-2-fluoro-2-deoxyglucose uptake in white adipose tissue on pediatric oncologic positron emission tomography (PET)/computed tomography (CT). <i>Pediatric Radiology</i> , 2020, 50, 524-533.	1.1	6
26	Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1110-1122.	5.1	63
27	Pictorial review of the clinical applications of MIBG in neuroblastoma: current practices. <i>Clinical and Translational Imaging</i> , 2020, 8, 483-507.	1.1	2
28	Dasatinib induces a dramatic response in a child with refractory juvenile xanthogranuloma with a novel MRC1-PDGFRB fusion. <i>Blood Advances</i> , 2020, 4, 2991-2995.	2.5	10
29	Long-term renal function after treatment for unilateral, nonsyndromic Wilms tumor. A report from the St. Jude Lifetime Cohort Study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28271.	0.8	24
30	PET with ¹⁸ F-Fluorodeoxyglucose/Computed Tomography in the Management of Pediatric Sarcoma. <i>PET Clinics</i> , 2020, 15, 333-347.	1.5	14
31	Efficacy and Safety of Limited-Margin Conformal Radiation Therapy for Pediatric Rhabdomyosarcoma: Long-Term Results of a Phase 2 Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 172-180.	0.4	6
32	Clinical manifestations of Pacak-Zhuang syndrome in a male pediatric patient. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28096.	0.8	4
33	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 2160-2169.	0.8	98
34	Evaluation of ¹¹ C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 312-319.	2.8	18
35	Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma. <i>Pediatric Radiology</i> , 2019, 49, 1545-1564.	1.1	71
36	A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. <i>Clinical Cancer Research</i> , 2019, 25, 6320-6328.	3.2	61

#	ARTICLE	IF	CITATIONS
37	Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study. <i>Clinical Cancer Research</i> , 2019, 25, 6044-6051.	3.2	20
38	Radioisotope Therapies: Iodine-131, I-131-MIBG, and Beyond. <i>Pediatric Oncology</i> , 2019, , 275-303.	0.5	0
39	Positron Emission Tomography Detects <i>In Vivo</i> Expression of Disialoganglioside GD2 in Mouse Models of Primary and Metastatic Osteosarcoma. <i>Cancer Research</i> , 2019, 79, 3112-3124.	0.4	28
40	Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27736.	0.8	8
41	Treatment patterns and disease outcomes for pediatric patients with refractory or recurrent Hodgkin lymphoma treated with curative-intent salvage radiotherapy. <i>Radiotherapy and Oncology</i> , 2019, 134, 89-95.	0.3	2
42	The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma. <i>Cancer</i> , 2019, 125, 290-297.	2.0	60
43	Pediatric Musculoskeletal Imaging. <i>PET Clinics</i> , 2019, 14, 145-174.	1.5	6
44	Analysis of quantitative [I-123] mIBG SPECT/CT in a phantom and in patients with neuroblastoma. <i>EJNMMI Physics</i> , 2019, 6, 31.	1.3	12
45	Radiomics Features Differentiate Between Normal and Tumoral High-Fdg Uptake. <i>Scientific Reports</i> , 2018, 8, 3913.	1.6	20
46	Age-Specific ¹⁸ F-FDG Image Processing Pipelines and Analysis Are Essential for Individual Mapping of Seizure Foci in Pediatric Patients with Intractable Epilepsy. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1590-1596.	2.8	20
47	Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. <i>Radiology</i> , 2018, 287, 303-312.	3.6	25
48	¹⁸ F-FDG Uptake During Early Adjuvant Chemotherapy Predicts Histologic Response in Pediatric and Young Adult Patients with Osteosarcoma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 25-30.	2.8	39
49	Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 292-305.	3.3	54
50	Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. <i>Journal of Nuclear Medicine</i> , 2018, 59, 502-508.	2.8	52
51	Radionuclide Imaging of Infection and Inflammation in Children: a Review. <i>Seminars in Nuclear Medicine</i> , 2018, 48, 148-165.	2.5	25
52	Efficacy of radioactive iodine treatment of graves' hyperthyroidism using a single calculated 131I dose. <i>Clinical Diabetes and Endocrinology</i> , 2018, 4, 20.	1.3	17
53	Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27408.	0.8	5
54	Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27417.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Guidelines on nuclear medicine imaging in neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2009-2024.	3.3	94
56	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. <i>Frontiers in Immunology</i> , 2018, 9, 1355.	2.2	66
57	FDG-PET CT in the evaluation of primary and secondary pancreatic malignancies. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27115.	0.8	7
58	The role of routine imaging in pediatric cutaneous melanoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27412.	0.8	7
59	Phase II trial of irinotecan/temozolomide/dinutuximab/granulocyte macrophage colony stimulating factor (I/T/DIN/GMCSF) in children with relapsed/refractory neuroblastoma (NBL): A report from the Children's Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10508-10508.	0.8	3
60	Long-term renal function after treatment for Wilms tumor: A report from the St. Jude Lifetime Cohort (SJLIFE) study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10566-10566.	0.8	0
61	Multi-level otsu method to define metabolic tumor volume in positron emission tomography. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 373-386.	1.0	1
62	11C-Methionine positron emission tomography delineates non-contrast enhancing tumor regions at high risk for recurrence in pediatric high-grade glioma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 163-170.	1.4	19
63	Optimization of Pediatric PET/CT. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 258-274.	2.5	53
64	The Role of 18 F-FDG-PET/CT in Pediatric Sarcoma. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 229-241.	2.5	82
65	Reply: The Need for Prudence When Using ¹⁸ F-FDG PET as a Reference Standard for Lymphoma Detection. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1355.1-1355.	2.8	2
66	Developmental Venous Anomalies Mimicking Neoplasm on 11C-Methionine PET and DSC Perfusion MRI. <i>Clinical Nuclear Medicine</i> , 2017, 42, e275-e276.	0.7	3
67	Irinotecan+temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 946-957.	5.1	205
68	Targeting Metabolic Reprogramming by Influenza Infection for Therapeutic Intervention. <i>Cell Reports</i> , 2017, 19, 1640-1653.	2.9	127
69	MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26545.	0.8	30
70	Compared to 123I-MIBG SPECT/CT, 18F-DOPA PET/CT provides accurate tumor extent in patients with extra-adrenal paraganglioma. <i>Annals of Nuclear Medicine</i> , 2017, 31, 357-365.	1.2	13
71	Role of MIBG Studies in Prognostication and Prediction of Metastatic Site Failure in Pediatric Patients with High-Risk Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S27-S28.	0.4	0
72	Cerebral Glucose Metabolism in Children with Craniopharyngioma Treated With Proton Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E568.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Management of Local-Regional Failure in Children With High-Risk Neuroblastoma: A Single Institution Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, E570-E571.	0.4	2
74	A Novel Methodology for Anatomically and Biologically Determined Clinical Target Volume Margin Estimation in Pediatric High Grade Glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S175-S176.	0.4	1
75	FDG PET/CT appearance of local osteosarcoma recurrences in pediatric patients. <i>Pediatric Radiology</i> , 2017, 47, 1800-1808.	1.1	16
76	A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2017, 23, 6441-6449.	3.2	116
77	CT-based SPECT attenuation correction and assessment of infarct size: results from a cardiac phantom study. <i>Annals of Nuclear Medicine</i> , 2017, 31, 764-772.	1.2	2
78	Nonrhabdomyosarcoma soft tissue sarcoma <scp>(NRSTS)</scp> in pediatric and young adult patients: Results from a prospective study using limitedâ€margin radiotherapy. <i>Cancer</i> , 2017, 123, 4419-4429.	2.0	15
79	Dose optimization: a review of CT imaging for PET attenuation correction. <i>Clinical and Translational Imaging</i> , 2017, 5, 359-371.	1.1	8
80	A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy. <i>International Journal of Cancer</i> , 2017, 141, 1469-1477.	2.3	42
81	¹²³ I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting method by an international panel. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 234-241.	3.3	52
82	Comparison of ¹¹ C-Methionine and ¹⁸ F-FDG PET/CT for Staging and Follow-up of Pediatric Lymphoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 419-424.	2.8	19
83	Early response rates and Curie scores at end of induction: An update from a phase II study of an anti-CD2 monoclonal antibody (mAb) with chemotherapy (CT) in newly diagnosed patients (pts) with high-risk (HR) neuroblastoma (NB).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10534-10534.	0.8	11
84	Risk factors associated with metastatic site failure in patients with high-risk neuroblastoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10557-10557.	0.8	0
85	Feasibility of Pegylated Interferon in Children and Young Adults With Resected Highâ€Risk Melanoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1207-1213.	0.8	20
86	¹³¹ I-Metaiodobenzylguanidine Theranostics in Neuroblastoma: Historical Perspectives; Practical Applications. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 184-202.	2.5	58
87	Comparison of ¹⁸ F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1381-1386.	0.8	81
88	Efficient automated syntheses of high specific activity ⁶ -[¹⁸ F]fluorodopamine using a diaryliodonium salt precursor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2016, 59, 30-34.	0.5	21
89	Assessment of Chemotherapy Response in Ewing Sarcoma. <i>Radiology</i> , 2016, 281, 647-649.	3.6	2
90	Phase II randomized trial of irinotecan/temozolomide (I/T) with temsirolimus (TEM) or dinutuximab plus granulocyte colony stimulating factor (DIN/GMCSF) in children with refractory or relapsed neuroblastoma: A report from the Childrenâ€™s Oncology Group (COG).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10502-10502.	0.8	4

#	ARTICLE	IF	CITATIONS
91	18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10549-10549.	0.8	9
92	Other Neoplasms. , 2016, , 337-347.		0
93	Computer-assisted Curie scoring for metaiodobenzylguanidine (mIBG) scans in patients with neuroblastoma.. Journal of Clinical Oncology, 2016, 34, 10559-10559.	0.8	0
94	Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2016, 34, 10526-10526.	0.8	0
95	Long-term Cerebral Glucose Distribution in Craniopharyngioma, Ependymoma, and Low-Grade Astrocytoma Patients After Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2015, 93, E505-E506.	0.4	0
96	Whole-Body Pediatric Neuroblastoma Imaging. Clinical Nuclear Medicine, 2015, 40, 737-739.	0.7	7
97	Impact of Post-Induction Curie Scores in High-Risk Neuroblastoma. Biology of Blood and Marrow Transplantation, 2015, 21, S107.	2.0	6
98	Ultralow dose computed tomography attenuation correction for pediatric PET CT using adaptive statistical iterative reconstruction. Medical Physics, 2015, 42, 558-566.	1.6	18
99	FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up. Pediatric Radiology, 2015, 45, 1308-1315.	1.1	25
100	Succinate Dehydrogenase Gene Mutations in Cardiac Paragangliomas. American Journal of Cardiology, 2015, 115, 1753-1759.	0.7	30
101	Establishing Age-Associated Normative Ranges of the Cerebral ¹⁸ F-FDG Uptake Ratio in Children. Journal of Nuclear Medicine, 2015, 56, 575-579.	2.8	17
102	131I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biology of Blood and Marrow Transplantation, 2015, 21, 673-681.	2.0	79
103	Postoperative cerebral glucose metabolism in pediatric patients receiving proton therapy for craniopharyngioma. Journal of Neurosurgery: Pediatrics, 2015, 16, 567-573.	0.8	11
104	Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI. British Journal of Cancer, 2015, 113, 1282-1288.	2.9	29
105	A Practical, Automated Synthesis of ¹⁸ F-Fluorobenzylguanidine for Clinical Use. ACS Chemical Neuroscience, 2015, 6, 1870-1879.	1.7	29
106	The role of ¹⁸ F-FDG PET/CT in the evaluation of residual disease in paediatric non-Hodgkin lymphoma. British Journal of Haematology, 2015, 168, 845-853.	1.2	37
107	Successive distinct high-grade gliomas in ² -hydroxyglutaric aciduria. Journal of Inherited Metabolic Disease, 2015, 38, 273-277.	1.7	20
108	68Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to 123I-MIBG SPECT/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 33-41.	3.3	46

#	ARTICLE	IF	CITATIONS
109	Early results from Children's Oncology Group (COG) ARST08P1: Pilot studies of cixutumumab or temozolomide with intensive multiagent chemotherapy for patients with metastatic rhabdomyosarcoma (RMS).. Journal of Clinical Oncology, 2015, 33, 10015-10015.	0.8	6
110	A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children's Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 10017-10017.	0.8	7
111	Comparison of ¹⁸ F-FDG-PET-CT and bone scintigraphy for evaluation of osseous metastases in newly diagnosed and recurrent osteosarcoma.. Journal of Clinical Oncology, 2015, 33, 10047-10047.	0.8	0
112	SUAREZ-CABRERA: Ultra-Low Dose Computed Tomography Attenuation Correction for Pediatric PET CT Using Adaptive Statistical Iterative Reconstruction (ASIR _a , _c). Medical Physics, 2015, 42, 3262-3262.	1.6	0
113	Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. European Journal of Haematology, 2014, 93, 377-383.	1.1	25
114	Pathologic Risk-based Adjuvant Chemotherapy for Unilateral Retinoblastoma Following Enucleation. Journal of Pediatric Hematology/Oncology, 2014, 36, e335-e340.	0.3	34
115	Cerebral glucose metabolism on positron emission tomography of children. Human Brain Mapping, 2014, 35, 2297-2309.	1.9	32
116	Regional Brain Glucose Metabolism and Neurocognitive Function in Adult Survivors of Childhood Cancer Treated with Cranial Radiation. Journal of Nuclear Medicine, 2014, 55, 1805-1810.	2.8	16
117	Renaissance of 18F-FDG Positron Emission Tomography in the Imaging of Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2337-2339.	1.8	18
118	Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma. Journal of Clinical Oncology, 2014, 32, 1445-1452.	0.8	134
119	Thyroid Cancer in Children. Journal of Nuclear Medicine, 2014, 55, 705-707.	2.8	13
120	Neuroblastoma: Functional Imaging. , 2014, , 429-445.		1
121	Validation of the MIBG SIOPEN scoring method in two independent high-risk neuroblastoma trials.. Journal of Clinical Oncology, 2014, 32, 10029-10029.	0.8	1
122	Validation of postinduction Curie scores in high-risk neuroblastoma.. Journal of Clinical Oncology, 2014, 32, 10031-10031.	0.8	1
123	Postoperative Metabolic Abnormality in Craniopharyngioma Patients Before Proton Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, S592.	0.4	0
124	Long-term Toxicities of a Prospective Trial Delivering Limited Margin 3DCRT/IMRT in Children With Rhabdomyosarcoma. International Journal of Radiation Oncology Biology Physics, 2013, 87, S69-S70.	0.4	1
125	A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1800-1808.	3.3	76
126	Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. American Journal of Hematology, 2013, 88, 116-119.	2.0	85

#	ARTICLE	IF	CITATIONS
127	Semiquantitative mlBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group. <i>Journal of Nuclear Medicine</i> , 2013, 54, 541-548.	2.8	169
128	The Role of PET/CT in Assessing Pulmonary Nodules in Children With Solid Malignancies. <i>American Journal of Roentgenology</i> , 2013, 201, W900-W905.	1.0	13
129	Evaluation of children with craniopharyngioma using carbon-11 methionine PET prior to proton therapy. <i>Neuro-Oncology</i> , 2013, 15, 506-510.	0.6	11
130	Evaluation of the Biodistribution of ¹¹ C-Methionine in Children and Young Adults. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1902-1908.	2.8	32
131	Comparison of PET-CT and conventional imaging in staging pediatric rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1128-1134.	0.8	92
132	MO-D-141-04: Brown Adipose Tissue Uptake Comparison Between Pharmacological and Environmental Control in a Pediatric PET Facility. <i>Medical Physics</i> , 2013, 40, 399-400.	1.6	0
133	⁶⁴ Cu- ² NH-Bn-DOTA-hu14.18K322A, a PET Radiotracer Targeting Neuroblastoma and Melanoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1772-1778.	2.8	26
134	Histiocyte-rich Xanthomatous Pseudotumor Mimicking Relapse on Positron Emission Tomography Imaging in an Adolescent With Primary Mediastinal Diffuse Large B-cell Lymphoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 232-235.	0.3	11
135	SNM Practice Guideline for Brain Death Scintigraphy 2.0. <i>Journal of Nuclear Medicine Technology</i> , 2012, 40, 198-203.	0.4	45
136	Evaluation of the Use of Carbon-11 Methionine PET Scans in Pediatric Patients With Craniopharyngioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, S163.	0.4	0
137	<i>Pediatric. Medical Radiology</i> , 2012, , 253-277.	0.0	0
138	PET/CT for staging and follow-up of pediatric nasopharyngeal carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1097-1106.	3.3	40
139	Role of lymphoscintigraphy and sentinel lymph node biopsy in the management of pediatric melanoma and sarcoma. <i>Pediatric Surgery International</i> , 2012, 28, 571-578.	0.6	27
140	Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project. <i>Radiology</i> , 2011, 261, 243-257.	3.6	386
141	Infiltrative cerebellar ganglioglioma: conventional and advanced MRI, proton MR spectroscopic, and FDG PET findings in an 18-month-old child. <i>Clinical Radiology</i> , 2011, 66, 194-201.	0.5	12
142	Pediatrics: Diagnosis of Neuroblastoma. <i>Seminars in Nuclear Medicine</i> , 2011, 41, 345-353.	2.5	86
143	FDG-PET/CT Prior or Subsequent to Radiation is a Poor Predictor of Local Outcome in Patients with Group III Rhabdomyosarcoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, S116.	0.4	5
144	Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. <i>Blood</i> , 2011, 117, 2614-2617.	0.6	95

#	ARTICLE	IF	CITATIONS
145	Retrospective Evaluation of PET-MRI Registration Algorithms. Journal of Digital Imaging, 2011, 24, 485-493.	1.6	21
146	Comparison of ¹²³ I-metaiodobenzylguanidine (MIBG) and ¹³¹ I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2011, 56, 1041-1045.	0.8	40
147	Evaluation of 18F-FDG PET and MRI Associations in Pediatric Diffuse Intrinsic Brain Stem Glioma: A Report from the Pediatric Brain Tumor Consortium. Journal of Nuclear Medicine, 2011, 52, 188-195.	2.8	44
148	Role of Limited Whole-Body PET/CT in Pediatric Lymphoma. American Journal of Roentgenology, 2011, 196, 1047-1055.	1.0	18
149	Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group. Clinical Cancer Research, 2011, 17, 6858-6866.	3.2	88
150	Conjoint Statement of the SNM, ACNM, and ABNM on Credentialing and Delineation of Privileges for Therapeutic Procedures Using Radiopharmaceuticals: TABLE 1.. Journal of Nuclear Medicine, 2011, 52, 323-326.	2.8	6
151	ABNM Position Statement: Nuclear Medicine Professional Competency and Scope of Practice. Journal of Nuclear Medicine, 2011, 52, 994-997.	2.8	9
152	FDG PET imaging of childhood sarcomas. Pediatric Blood and Cancer, 2010, 54, 222-227.	0.8	51
153	FDG positron emission tomography/computed tomography studies of Wilms's tumor. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1300-1308.	3.3	47
154	Renal Function in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial. Journal of Pediatrics, 2010, 156, 66-70.e1.	0.9	109
155	Criteria for evaluation of disease extent by ¹²³ I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. British Journal of Cancer, 2010, 102, 1319-1326.	2.9	189
156	Utility of bone marrow biopsy at diagnosis in pediatric Hodgkin's lymphoma. Haematologica, 2010, 95, 1691-1696.	1.7	16
157	Reply: ¹²³ I-MIBG Scintigraphy and ¹⁸ F-FDG PET in Neuroblastoma. Journal of Nuclear Medicine, 2010, 51, 331-331.	2.8	2
158	MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study.. Journal of Clinical Oncology, 2010, 28, 9516-9516.	0.8	4
159	¹²³ I-MIBG Scintigraphy and ¹⁸ F-FDG PET in Neuroblastoma. Journal of Nuclear Medicine, 2009, 50, 1237-1243.	2.8	179
160	Early Results of a Prospective Study Delivering Limited Margin Radiotherapy for Pediatric Patients with Ewing's Sarcoma Family of Tumors. International Journal of Radiation Oncology Biology Physics, 2009, 75, S41.	0.4	0
161	Feasibility of Biological Image Guided Radiotherapy for Pediatric Rhabdomyosarcoma Based on FDG PET. International Journal of Radiation Oncology Biology Physics, 2009, 75, S512.	0.4	0
162	PET-CT of the Normal Spinal Cord in Children. Academic Radiology, 2009, 16, 881-885.	1.3	10

#	ARTICLE	IF	CITATIONS
163	Bone and [¹⁸ F]Fluorodeoxyglucose positron-emission tomography/computed tomography scanning for the assessment of osseous involvement in Hodgkin lymphoma in children and young adults. <i>Leukemia and Lymphoma</i> , 2009, 50, 1794-1802.	0.6	25
164	Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with Hodgkin lymphoma. <i>Pediatric Blood and Cancer</i> , 2008, 51, 198-203.	0.8	23
165	Pediatric Positron Emission Tomography-Computed Tomography Protocol Considerations. <i>Seminars in Ultrasound, CT and MRI</i> , 2008, 29, 271-276.	0.7	14
166	PET/CT in the Evaluation of Neuroblastoma. <i>PET Clinics</i> , 2008, 3, 551-561.	1.5	11
167	Procedure Guideline for Diuretic Renography in Children 3.0. <i>Journal of Nuclear Medicine Technology</i> , 2008, 36, 162-168.	0.4	74
168	Comparison of 18F Fluorodeoxyglucose PET with Ga-67 scintigraphy and conventional imaging modalities in pediatric lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 699-707.	0.6	54
169	PET and PET/CT in Pediatric Oncology. <i>Seminars in Nuclear Medicine</i> , 2007, 37, 316-331.	2.5	115
170	Differentiating Adrenal Adenomas From Nonadenomas Using 18F-FDG PET/CT. <i>Academic Radiology</i> , 2007, 14, 468-475.	1.3	98
171	PET-CT in pediatric Langerhans cell histiocytosis. <i>Pediatric Radiology</i> , 2007, 37, 615-622.	1.1	101
172	<i>Pediatric Oncology</i> , 2007, , 404-418.		1
173	TH-E-M100J-07: Changes in Standardized Uptake Value of Brain Tissues in Pediatric Brain Tumor Patients Treated with Chemoradiotherapy. <i>Medical Physics</i> , 2007, 34, 2650-2650.	1.6	0
174	18F-Fluorodeoxyglucose PET/CT in Childhood Lymphoma. <i>PET Clinics</i> , 2006, 1, 265-273.	1.5	3
175	Differentiation Between Carcinoid and Sarcoid With F-18 FDG PET and In-111 Pentetreotide. <i>Clinical Nuclear Medicine</i> , 2006, 31, 197-200.	0.7	19
176	Multimodality Imaging of Malignant Pheochromocytoma. <i>Clinical Nuclear Medicine</i> , 2006, 31, 822-825.	0.7	11
177	Radiation-Induced Osteosarcoma and Papillary Carcinoma of the Thyroid. <i>Clinical Nuclear Medicine</i> , 2006, 31, 5-8.	0.7	5
178	FDG PET for the study of primary hepatic malignancies in children. <i>Pediatric Blood and Cancer</i> , 2006, 47, 51-55.	0.8	31
179	Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2006, 47, 865-874.	0.8	79
180	Current Trends in Functional Imaging of Pheochromocytomas and Paragangliomas. <i>Annals of the New York Academy of Sciences</i> , 2006, 1073, 374-382.	1.8	50

#	ARTICLE	IF	CITATIONS
181	Courses of Malignant Pheochromocytoma: Implications for Therapy. Annals of the New York Academy of Sciences, 2006, 1073, 505-511.	1.8	25
182	Gene Expression Profiling of Benign and Malignant Pheochromocytoma. Annals of the New York Academy of Sciences, 2006, 1073, 541-556.	1.8	59
183	PET/CT Characterization of Fibroosseous Defects in Children:18F-FDG Uptake Can Mimic Metastatic Disease. American Journal of Roentgenology, 2006, 187, 1124-1128.	1.0	62
184	Use of [18F]Fluorodeoxyglucose Positron Emission Tomography in Evaluating Locally Recurrent and Metastatic Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2665-2671.	1.8	109
185	PET Imaging in Pediatric Disorders. , 2006, , 337-357.		1
186	Amiodarone-Induced Hyperthyroidism in a Patient with Functioning Papillary Carcinoma of the Thyroid and Extensive Hepatic Metastases. Thyroid, 2005, 15, 1337-1340.	2.4	9
187	Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocrine-Related Cancer, 2005, 12, 263-272.	1.6	47
188	PET in pediatric diseases. Radiologic Clinics of North America, 2005, 43, 135-152.	0.9	28
189	New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas. Trends in Endocrinology and Metabolism, 2005, 16, 66-72.	3.1	65
190	Malignant pheochromocytoma: current status and initiatives for future progress. Endocrine-Related Cancer, 2004, 11, 423-436.	1.6	299
191	PET imaging in pediatric oncology. Pediatric Radiology, 2004, 34, 199-204.	1.1	39
192	Technical issues in performing PET studies in pediatric patients. Journal of Nuclear Medicine Technology, 2004, 32, 5-9; quiz 10-1.	0.4	20
193	Thoracic neural crest tumors in Beckwith-Wiedemann syndrome. Medical and Pediatric Oncology, 2003, 41, 468-469.	1.0	2
194	Is preoperative iodine 123 meta-iodobenzylguanidine scintigraphy routinely necessary before initial adrenalectomy for pheochromocytoma?. Surgery, 2003, 134, 918-922.	1.0	79
195	Role of MR Imaging and Iodine 123 MIBG Scintigraphy in Staging of Pediatric Neuroblastoma [letter]. Radiology, 2003, 227, 908-909.	3.6	10
196	Advances in Imaging of Nonthyroid Endocrine Neoplasms. Problems in General Surgery, 2003, 20, 11-20.	0.2	1
197	Procedure guideline for brain death scintigraphy. Journal of Nuclear Medicine, 2003, 44, 846-51.	2.8	34
198	Increasing efficacy and safety of treatments of patients with well-differentiated thyroid carcinoma by measuring body retentions of 131I. Journal of Nuclear Medicine, 2003, 44, 898-903.	2.8	43

#	ARTICLE	IF	CITATIONS
199	Pilot Study of Iodine-131- ¹³¹ I-Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2142-2149.	0.8	132
200	Mediastinal Seminoma in a Patient With Wiskott-Aldrich Syndrome. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 672-676.	0.3	6
201	Radioisotope diagnosis and therapy of malignant pheochromocytoma. <i>Trends in Endocrinology and Metabolism</i> , 2001, 12, 469-475.	3.1	68
202	A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3641-3646.	1.8	51
203	A "Pheo" Lurks: Novel Approaches for Locating Occult Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3641-3646.	1.8	40
204	Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-D-glucose PET. <i>Radiology</i> , 1999, 212, 35-41.	3.6	299
205	Treatment of Malignant Pheochromocytomas With ¹³¹ I-Metaiodobenzylguanidine and Chemotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1999, 22, 364-370.	0.6	86
206	Paget Disease of the Thumb. <i>Clinical Nuclear Medicine</i> , 1999, 24, 613-614.	0.7	2
207	Resting coronary flow and coronary flow reserve in human infants after repair or palliation of congenital heart defects as measured by positron emission tomography. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1998, 115, 103-110.	0.4	114
208	Intrapericardial paragangliomas (pheochromocytomas): imaging features.. <i>American Journal of Roentgenology</i> , 1997, 168, 109-113.	1.0	99
209	Distribution of pulmonary blood flow and total lung water during partial liquid ventilation in acute lung injury. <i>Surgery</i> , 1997, 122, 313-323.	1.0	46
210	Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy. <i>Hepatology</i> , 1997, 26, 277-282.	3.6	26
211	PET FDG Studies of Wilms Tumors. <i>The American Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 334-338.	1.3	45
212	Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.. <i>Radiology</i> , 1996, 199, 743-750.	3.6	158
213	Survival of Patients with Neuroblastoma Treated with ¹²⁵ I-MIBG. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 144-148.	0.6	31
214	Splenosis in a Patient With Autoimmune Thrombocytopenia. <i>Clinical Nuclear Medicine</i> , 1996, 21, 61-62.	0.7	0
215	Intraluminal Hematoma. <i>Clinical Nuclear Medicine</i> , 1995, 20, 1095.	0.7	0
216	FDG PET imaging of paragangliomas of the neck: comparison with MIBG SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995, 22, 1347-1350.	2.2	20

#	ARTICLE	IF	CITATIONS
217	Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.. Radiology, 1995, 194, 495-500.	3.6	90
218	Inhibition of Neutral Amino Acid Transport Across the Human Blood-Brain Barrier by Phenylalanine. Journal of Neurochemistry, 1995, 64, 1252-1257.	2.1	52
219	Efficacy of anterior gastric fundoplication in the treatment of gastroesophageal reflux in infants and children. Journal of Pediatric Surgery, 1994, 29, 1071-1075.	0.8	14
220	Multiple Chemodectomas. Clinical Nuclear Medicine, 1994, 19, 527-531.	0.7	8
221	MIBG detection of hepatic neuroblastoma: Correlation with CT, US and surgical findings. Pediatric Radiology, 1993, 23, 276-280.	1.1	16
222	Pheochromocytomas that do not accumulate metaiodobenzylguanidine: localization with PET and administration of FDG.. Radiology, 1993, 186, 711-715.	3.6	89
223	Postprocedural symptoms in children who undergo imaging studies of the urinary tract: is it the contrast material or the catheter?. Radiology, 1992, 182, 727-730.	3.6	45
224	Splenic Infarction Detection by In-111 Leukocyte Scintigraphy. Clinical Nuclear Medicine, 1992, 17, 822.	0.7	2
225	Bilateral Testicular Neuroblastoma Scintigraphic Depiction and Therapy with I-131 MIBG. Clinical Nuclear Medicine, 1992, 17, 638-642.	0.7	5
226	131-I-Metaiodobenzylguanidine Treatment in Patients with Refractory Advanced Neuroblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 1992, 15, 226-232.	0.6	50
227	Flare Response in Ewing's Sarcoma. Clinical Nuclear Medicine, 1991, 16, 807-809.	0.7	2
228	Effect of Aspartame-Derived Phenylalanine on Neutral Amino Acid Uptake in Human Brain: A Positron Emission Tomography Study. Journal of Neurochemistry, 1991, 56, 1526-1535.	2.1	16
229	Use of [11C]Aminocyclohexanecarboxylate for the Measurement of Amino Acid Uptake and Distribution Volume in Human Brain. Journal of Cerebral Blood Flow and Metabolism, 1990, 10, 727-739.	2.4	36
230	The Role of Imaging Tests in the Diagnosis of Thyroid Carcinoma. Endocrinology and Metabolism Clinics of North America, 1990, 19, 523-543.	1.2	26
231	Kasabach-Merritt syndrome: Treatment with epsilon-aminocaproic acid and assessment by indium 111 platelet scintigraphy. Journal of Pediatrics, 1990, 117, 746-749.	0.9	34
232	Quantification of Bone Mineralization by Dual Photon Absorptiometry in Osteopetrosis. Clinical Nuclear Medicine, 1989, 14, 544-545.	0.7	0
233	Iodine-131 Metaiodobenzylguanidine Uptake in Infantile Myofibromatosis. Clinical Nuclear Medicine, 1989, 14, 344-346.	0.7	20
234	Platelet reactivity in human aortic grafts: A prospective, randomized midterm study of platelet adherence and release products in Dacron and polytetrafluoroethylene conduits. Journal of Vascular Surgery, 1989, 9, 0234-0243.	0.6	7

#	ARTICLE	IF	CITATIONS
235	Scintigraphic detection of sinusitis. European Journal of Nuclear Medicine and Molecular Imaging, 1988, 14, 552-4.	2.2	1
236	Thyroid hormone analog inhibition of hepatic 5 ^α -iodothyrohine deiodinase activity. Journal of Endocrinological Investigation, 1988, 11, 657-661.	1.8	6
237	Hot Nodule After Fine Needle Aspiration. Clinical Nuclear Medicine, 1988, 13, 131.	0.7	1
238	Unusual Uptake of In-111 Labeled Platelets in a Patient with Polycythemia. Clinical Nuclear Medicine, 1988, 13, 917-918.	0.7	0
239	Dual Photon Absorptiometry The Importance of Clinical Correlation. Clinical Nuclear Medicine, 1988, 13, 175-176.	0.7	1
240	Uptake of Tc-99m MDP in Soft Tissue Calcific Deposits Due to the Tumor Lysis Syndrome. Clinical Nuclear Medicine, 1988, 13, 765-767.	0.7	2
241	Scintigraphic Portrayal of the Syndrome of Multiple Endocrine Neoplasia Type-2B. Clinical Nuclear Medicine, 1988, 13, 433-437.	0.7	11
242	SPECT Imaging of Myocarditis. Clinical Nuclear Medicine, 1987, 12, 841-842.	0.7	4
243	Pheochromocytoma, polycythemia and venous thrombosis. American Journal of Medicine, 1987, 83, 773-776.	0.6	29
244	Primary Extra-Adrenal Pheochromocytoma Positive I-123 MIBG Imaging with Negative I-131 MIBG Imaging. Clinical Nuclear Medicine, 1986, 11, 851-854.	0.7	52
245	Simultaneous pancreatic-renal transplant scintigraphy. American Journal of Roentgenology, 1986, 147, 1193-1196.	1.0	14
246	TSH and Thyroidal Responses to Continuous and Intermittent TRH Administration. , 1986, , 285-290.		0
247	Caloric Restriction Does not Alter Thyrotropin Secretion in Hypothyroidism*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 1076-1080.	1.8	2
248	<i>α</i> -Adrenergic Antagonist Inhibition of Hepatic 3,5,3 ^α -Triiodothyronine Production*. Endocrinology, 1984, 115, 858-861.	1.4	16
249	Reverse Triiodothyronine Does Not Alter Pituitary Thyroid Function in Normal Subjects*. Journal of Clinical Endocrinology and Metabolism, 1984, 58, 1184-1187.	1.8	15
250	Preincubation of Thyroxine with Sulfhydryl-Reducing Agents Does Not Stimulate Thyroxine Inner or Outer Ring Deiodination*. Endocrinology, 1983, 113, 851-854.	1.4	3